References

1. Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: An extensive review. Psychother Psychosom 2009; 78(5): 285-97.
2. Solomon DA, Leon AC, Coryell WH, Endicott J, Li C, Fiedorowicz JG, et al. Longitudinal course of bipolar I disorder: Duration of mood episodes. Arch Gen Psychiatry 2010; 67: 339-47.
3. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163: 217-24.
4. Oswald P, Souery D, Kasper S, Lecrubier Y, Montgomery S, Wyckaert S, et al.  Current issues in bipolar disorder: A critical review. Eur Neuropsychopharmacol 2007; 17: 687-95.
5. Fagiolini A, Frank E, Axelson DA, Birmaher B, Cheng Y, Curet DE, et al. Enhancing outcomes in patients with bipolar disorder: Results from the Bipolar Disorder Center for Pennsylvanians Study. Bipolar Disord 2009; 11: 382-90.
6. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-7.
7. Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of mental disorders in the Nigerian Survey of Mental Health and Well-Being. Br J Psychiatry 2006; 188: 465-71.
8. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP,
   Ruan WJ, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66(10): 1205-15.
9. Hebrani P, Moharreri F, Behdani F. [The assessment of prevalence of psychiatric disorders among bipolar disorders patients' children in comparison with control group]. Medical journal of Mashhad University of Medical Sciences 2011; 53(4): 222-7. (Persian)
10. American Psychiatric Association. DSM-IV-TR: Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric; 2000.
11. Kahani M, Talaei A, Mokhber N, Fayyazi Bordbar M, Dolatshahi M. [Executive functions in patients with bipolar I disorder in recovery phase: A case-control study]. Journal of Mazandaran University of Medical Sciences 2013; 23: 110-18. (Persian)
12. Toubaei Sh, Hadi N, Hedayati A, Montazeri A. [Comparison of health related quality of life between bipolar patients and healthy controls]. Journal of fundamentals of mental health 2012; 14(1): 54-63. (Persian)
13. Ebrahimi A, Talaei A, Mokhber N, Akbarzadeh F, Akhlaghi S, Nejati R, et al. [Efficacy of addition of folic acid to sodium valproate in treatment of acute mania, a double blind clinical trial study]. Medical journal of Mashhad University of Medical Sciences 2014; 57(1): 398-405. (Persian)
14. Masoudi Sh, Tabatabaei SM, Modarres Gharavi M, Ghanbari Hashemabadi BA. [The effect of group cognitive-behavioral therapy on outcomes of bipolar I disorder]. Journal of fundamentals of mental health 2009; 10(4): 289-98. (Persian)
15. Barde M, Bellivier F. Treatment of bipolar disorder. Rev Pract 2014; 64(9): 1195-202. (French)
16. Boon G. Mood stabilizers. Medicine (United Kingdom) 2012; 40(12): 679-80.
17. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan CM. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update o f CANMAT guidelines for the management of patients with bipolar

17.  Khoo JP. Mood stabilizers. Aust Prescriber 2012; 35(5): 164-8.

                 disorder: Update 2009. Bipolar Disord    2009; 11(3): 225-55.

1.  Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10(2): 85-116.
2. 20.  Goodwin GM. Evidence-based guidelines for treating bipolar disorder: Revised second edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23(4): 346-88.
3. Connolly KR, Thase ME. The clinical management of bipolar disorder: A review of evidence-based guidelines. Prim Care Compan CNS Disord 2011; 13(4): 649-60.
4. Nivoli AM, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, Gonzalez-Pinto A, et al. New treatment guidelines f or a cut e bipolar depression: A systematic review. J Affect Disord 2011; 129(1-3): 14-26.
5. Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s synopsis of psychiatry: behavioral sciences and clinical psychiatry. 11^th ed. New York: Wolters Kluwer; 2015: 347-87.
6. Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009; 5(5): 539-51.
7. Vieta E. Mood stabilization in the treatment of bipolar disorder: Focus on quetiapine. Hum Psychopharmacol 2005; 20: 225-36.
8. Vieta E, Calabrese JR, Goikolea JM, Raines S, McFadden W. BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9: 413-25.
9. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analyses of two international, double-blind, randomized, placebo-controlled studies. Curr Med Res Opin 2005; 21(6): 923-34.
10. Stahl S. Stahl’s essential psychopharmacology: Neuroscientific basis and practical application. 4^th ed. Cambridge: Cambridge University; 2013.
11. Dando TM, Keating GM. Quetiapine: A review of its use in acute mania and depression associated with bipolar disorder. Drugs 2005; 65(17): 2533-51.
12. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6(3): 213-23.
13. Sussman N, Mullen J, Paulsson B, Vagerö M. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. J Affect Disord 2007; 100(Suppl 1): S55-63.
14. McIntyre RS, Konarski JZ, Jones M, Paulsson B. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 2007; 100 (Suppl 1): S5-14.
15. Vella T, Mifsud J. Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring. J Pharm Pharmacol 2014; 66(6): 747-59.
16. Huang CC, Wei IH. Unexpected interaction between quetiapine and valproate in patients with bipolar disorder. Gen Hosp Psychiatry 2010; 32(4): 446.
17. Halaby A, Haddad R, Naja WJ. Hyperammonemia induced by interaction of valproate and quetiapine. Curr Drug Saf 2013; 8(4): 284-6.

      36. Brahm NC1, Gutierres SL, Carnahan RM. Quetiapine for acute mania in bipolar disorder.  Am J Health Syst Pharm 2007; 64(10): 1045-53.

37. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, et al. A double-blind, randomized, pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 305-13.

38. Feifel D, Galangue B. Single-blind comparison of rapid dose administration of divalproex ER versus quetiapine in patients with acute bipolar mania. Clin Neurosci 2011; 8(1): 29-35.

39. Langosch JM, Drieling T, Biedermann NC, Born C, Sasse J, Bauer H, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008; 28(5): 555-60.